Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07016542
Recruiting Observational

Cohort for Monitoring Patients With Venous Thromboembolic Disease

NCT07016542 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Rouen
Phase
Observational
Started
2019-11-18
Last updated
2025-06-11

Condition(s) studied

Venous Thromboembolic Disease

Study summary

Venous thromboembolic disease is a common pathology in the general population (1.5/1000), the prognosis of which depends in particular on the risk of recurrence. This risk depends essentially on whether the thrombotic episode was provoked or not. Thus, patients who present a thromboembolic event without any contributing factor have a high risk of recurrence, which encourages clinicians to continue anticoagulant treatment for a long time. However, anticoagulant treatment is the leading cause of hospitalization for iatrogenic causes and the leading cause of iatrogenic mortality. The benefit-risk balance of treatment must be evaluated regularly, which requires a good knowledge of the risk factors for thrombotic recurrence and the risk factors for hemorrhage.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Any patient over 18 years of age who has experienced at least one venous thromboembolic episode: * Deep vein thrombosis confirmed by Doppler ultrasound or CT venography, * Pulmonary embolism confirmed by CT angiography, ventilation/perfusion scan, or confirmed DVT episode with respiratory signs consistent with PE. 2. Hospitalization in the Internal Medicine Department 3. Consultation by an Internal Medicine physician 4. File presented at the thrombosis multidisciplinary meeting Exclusion Criteria: Thrombosis not meeting the inclusion criteria (cerebral venous thrombosis, mesenteric)

Primary outcome measure(s)

  • Rate of recurrence in patients treated with venous thromboembolic disease (VTE) — 12 years
    Evaluation of the number of hospitalizations or consultations for a venous thrombotic recurrence
  • Rate of bleeding complications in patients treated with venous thromboembolic disease (VTE) — 12 years
    Evaluation of the number of hospitalizations or consultations for a hemorrhagic complication.

Trial sites (1)

FacilityCityRegionStatus
University Hospital of Rouen Rouen France Recruiting

More University Hospital, Rouen trials in France

STRucturation of Transcript Analysis of Genes Involved in Hereditary Cancers Recruiting
Benefit of Sleep Quality Monitoring by EEG in ICU Recruiting
In Utero Alcoholic Exposure: PlGF, Biomarker of Fetal Brain Lesions Recruiting
De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer Starting soon
Evaluation of Gynecological and Sexual Sequelae Recruiting

Other trials for the same condition

Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure Recruiting
Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study Recruiting
Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets Recruiting
THROmbinography in Pregnant Woman and in Vitro Action of Low Molecular Weight HEparin Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07016542 on ClinicalTrials.gov ↗ ← All trials in France